Pharmacokinetic Study of DA-020
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-55
SponsorApplied Biology, Inc.
About this trial
Pharmacokinetic Study of DA-020
Eligibility criteria
Qualifiers
Healthy females, age 18-55
BMI: 18-30 kg/m²
Fitzpatrick Skin Types I-IV (to standardize absorption risk)
Scalp free from irritation, dermatologic disease, or damage
Disqualifiers
History of cardiovascular disease, hypertension, or arrhythmia
Scalp infections, wounds, or significant hair loss
Recent use of medications that interfere with CYP enzymes or adrenergic systems
Known sensitivity to phenylephrine or ethanol
Trial design
Treatments tested in this trial
- DA-020 (0.1%)
- DA-020 (0.2%)
- DA-020 (0.5%)
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Applied Biology, Inc.
Lead sponsor
Daniel Alain, Inc.
Collaborator
Follea International Limited
Collaborator
Source ClinicalTrials.gov